---
title: "Buntanetap: Parkinson's Drug Pipeline"
description: "An oral candidate aimed at reducing several nerve-damaging proteins at once. Company-reported Phase 3 results in early Parkinson's are mixed, and independent peer-reviewed data are still limited."
canonical_url: "https://parkinsonspathways.com/pipeline/buntanetap"
development_stage: "Phase 3: large human trials"
last_updated: 2026-06-01
source: "Parkinson's Pathways"
---
# Buntanetap

**Stage:** Phase 3  ·  **Type:** Disease-modifying

**Developer:** Annovis Bio

**How it works:** An oral drug intended to lower the production of several nerve-damaging proteins at once (including alpha-synuclein, tau and amyloid) by acting on their messenger RNA.

**Target:** Multiple neurotoxic proteins (incl. alpha-synuclein)

**Who it's for:** People with early Parkinson's.

**Key trials:** NCT05357989

**Last reviewed:** 2026-06-01


## What it is

Buntanetap (formerly posiphen) is a pill designed to turn down the body's production of several proteins thought to drive nerve damage in Parkinson's and Alzheimer's, rather than targeting just one. The hope is that hitting multiple proteins could protect brain cells.

## Where it stands

Annovis Bio has run a Phase 3 study in early Parkinson's and reported results through company announcements. The path to any FDA submission, and how regulators view the data, is not yet settled.

## What the data shows so far

The Phase 3 early-Parkinson's study enrolled several hundred people over about six months. The company has described improvements on Parkinson's rating scales in parts of the study, but reported results have been mixed across endpoints and subgroups, and should be judged against the pre-specified primary endpoint in full peer-reviewed publications rather than press releases.

## What families should know

This is an early, much-debated program. Encouraging company statements have not yet been matched by clear, independently published Phase 3 evidence that it slows or meaningfully changes Parkinson's.

## Caveats

Efficacy is not established. Reported results come largely from company announcements and have been mixed; some highlighted benefits were in subgroups, which can vanish in confirmatory trials. Treat with caution until peer-reviewed Phase 3 data are available.

## Timeline

_Most recent first._

- **2023-2024**, Phase 3 trial in early Parkinson's conducted; results reported by the company.

## Sources

- [Phase 3 early-PD study on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05357989)

_Last reviewed: 2026-06-01._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)